SecBot SecBot
8-K ·Filed Apr 16, 2026

ABT

ABBOTT LABORATORIES
BEARISH
Impact 8/10
Horizonimmediate Processed7mo ago SEC0001628280-26-025365
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The stock is likely to decline on the guidance miss despite a solid quarter, as the Exact Sciences acquisition dilution outweighs near-term growth. Monitor second-quarter EPS guidance of $1.25-$1.31 for signs of recovery.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$95.48
T+0 close · Apr 16, 2026 · via day close
Latest settled
−1.62%
T+60 · $93.93
Vs SPY
−9.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $95.48entry
  2. T+1 · 7mo ago +1.40%α +0.19% · $96.82
  3. T+5 · 7mo ago −3.19%α −4.18% · $92.43
  4. T+20 · 6mo ago −12.20%α −18.01% · $83.83
  5. T+60 · 4mo ago −1.62%α −9.21% · $93.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abbott Laboratories reported first-quarter 2026 adjusted EPS of $1.15, a 6% year-over-year increase, but missed consensus by $0.00. Revenue of $11.16B grew 7.8% YoY. The company lowered full-year 2026 adjusted EPS guidance to $5.38-$5.58 (from $5.55-$5.80) due to $0.20 dilution from the Exact Sciences acquisition. Despite strong growth in Established Pharmaceuticals and Medical Devices, the guidance reduction drives a bearish sentiment.

Key Financial Metrics

EPS
$1.15
est $1.15 · 0.0%
Revenue
$11.2B
est $11.0B · +1.5% · +7.8% YoY
Rating
miss

Key Facts

  • First-quarter 2026 adjusted EPS was $1.15, missing consensus of $1.15 by $0.00 but up 6% YoY
  • First-quarter 2026 revenue was $11.16B, beating consensus of $11.00B and growing 7.8% YoY
  • Full-year 2026 adjusted EPS guidance was lowered to $5.38-$5.58 from $5.55-$5.80 due to $0.20 dilution from the Exact Sciences acquisition
  • The company completed the acquisition of Exact Sciences, establishing a new oncology diagnostics business
  • Medical Devices sales grew 13.2% YoY, driven by double-digit growth in Electrophysiology, Heart Failure, and Rhythm Management

Financial Impact

The guidance reduction of $0.20 at the midpoint implies a $0.7B annual EPS impact, offsetting the strong quarterly beat

epsguidancedilution

Risk Factors

  • Exact Sciences acquisition may underperform, leading to further dilution
  • Integration risks from the Exact Sciences acquisition
  • Continued pricing pressures in the Nutrition segment

Market Snapshot

Price
$98.96
Volume
479
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
74% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-025365
Document: abt-20260416.htm0001628280-26-025365
Document: 0001628280-26-025365-index-headers.html0001628280-26-025365
Document: 0001628280-26-025365-index.html0001628280-26-025365
Document: 0001628280-26-025365.txt0001628280-26-025365
8-K Data (Synthetic)0001628280-26-025365

Track record

38 reports on ABT

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +17.16% at T+20 after the Jul 1, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 5, 202611d ago 144 Neutral 2/10 Entry $109.93 Now $107.45 −2.26% settles Dec 7
  2. Oct 27, 202620d ago ANALYST-DOWNGRADE Neutral 2/10 Entry $103.10 Now $107.45 +4.22% settles Nov 24
  3. Oct 27, 202621d ago Court Ruling Neutral 1/10 Entry $102.64 Now $107.45 +4.69% settles Nov 25
  4. Oct 21, 202626d ago Institutional Cluster Mixed 4/10 Entry $102.51 Now $107.45 +4.82% settles Nov 19
  5. Oct 21, 202626d ago 8-K Bullish 6/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
  6. Oct 21, 202626d ago 8-K Bearish 6/10 No price data
  7. Oct 21, 202626d ago Press Release Neutral 4/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
  8. Oct 20, 202628d ago Court Ruling Neutral 1/10 Entry $100.51 Now $107.45 +6.90% settles Nov 18
  9. Oct 16, 20264w ago Court Ruling Neutral 2/10 Entry $104.06 to $107.45 Now $107.45 +3.26% ▲ +3.26% +6.72% vs SPY
  10. Oct 15, 20264w ago Court Ruling Bullish 5/10 Entry $104.89 to $108.52 Now $107.45 +2.44% ▲ +3.46% +4.62% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026